227.59
price down icon0.14%   -0.44
after-market After Hours: 228.00 0.41 +0.18%
loading
Abbvie Inc stock is traded at $227.59, with a volume of 2.71M. It is down -0.14% in the last 24 hours and up +3.22% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$228.03
Open:
$227
24h Volume:
2.71M
Relative Volume:
0.51
Market Cap:
$402.05B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
108.31
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
-1.59%
1M Performance:
+3.22%
6M Performance:
+18.39%
1Y Performance:
+20.05%
1-Day Range:
Value
$224.31
$228.40
1-Week Range:
Value
$224.31
$232.16
52-Week Range:
Value
$163.81
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.59 402.83B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
LLY
Lilly Eli Co
820.29 740.84B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.93 458.49B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.39 250.00B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.03 219.80B 63.43B 16.42B 14.72B 6.4861

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
11:28 AM

AbbVie: Deep Discount Before Earnings (NYSE:ABBV) - Seeking Alpha

11:28 AM
pulisher
10:36 AM

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? - sharewise.com

10:36 AM
pulisher
09:00 AM

Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM - WV News

09:00 AM
pulisher
08:27 AM

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool

08:27 AM
pulisher
Oct 27, 2025

Can AbbVie Inc. stock attract analyst upgrades2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest - Barchart.com

Oct 27, 2025
pulisher
Oct 27, 2025

AbbVie Defends Challenge Of Colorado's Discount Drug Law - Law360

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock withstand economic slowdownEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock extend growth storyPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock surprise markets with earningsPortfolio Growth Summary & Real-Time Chart Pattern Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock a buy on dips2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock resilient to inflationJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Ophthalmic Drugs Market Set for Dynamic Growth with Key Players Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Fish Skin Disease Market to Witness Remarkable Growth With GSK - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 20252025 Top Gainers & High Yield Stock Recommendations - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How AbbVie Inc. stock performs in rising dollar environmentWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

How sentiment analysis helps forecast AbbVie Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Why AbbVie Inc. (4AB) stock stays on top picksPortfolio Risk Summary & Technical Pattern Alert System - newser.com

Oct 26, 2025
pulisher
Oct 25, 2025

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance

Oct 25, 2025
pulisher
Oct 25, 2025

AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025
pulisher
Oct 24, 2025

AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks

Oct 24, 2025
pulisher
Oct 24, 2025

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com

Oct 24, 2025
pulisher
Oct 23, 2025

AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism - ts2.tech

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

AbbVie Up More Than 30% in 6 Months: How to Play the Stock - The Globe and Mail

Oct 22, 2025
pulisher
Oct 22, 2025

YieldBoost AbbVie From 2.9% To 6.9% Using Options - Nasdaq

Oct 22, 2025
pulisher
Oct 22, 2025

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' - Benzinga

Oct 22, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$186.93
price down icon 1.78%
drug_manufacturers_general NVS
$123.39
price down icon 4.45%
drug_manufacturers_general MRK
$87.03
price down icon 1.00%
drug_manufacturers_general NVO
$52.05
price down icon 1.68%
$292.09
price up icon 0.28%
Cap:     |  Volume (24h):